ALTHOUGH stroke is one of the leading causes of death and disability, T&T lacks a national stroke registry. This means we do ...

Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

CHRISTUS Health is expanding neurological care to treat strokes and aneurysms in San Antonio's Westover Hills community.

Caffeine appears to do the opposite of what you might think when it comes to the heart. Scientists have found that a cup of ...

Those who have undergone successful corrective procedures for irregular heart beats may no longer need to commit to long-term ...

OCEAN, said Albert, provides important risk-benefit data that doctors can now use in discussions with their patients. For ...

The drug targets the PCSK9 protein, and could give millions of people a more affordable option to reduce their heart disease ...

OCEAN was an open-label trial conducted in Australia, Belgium, Canada, China, Germany, and Israel. Eligible participants had ...

The results have potential to change clinical practice.NEW ORLEANS — Left atrial appendage closure in patients with atrial ...

For some people with high cholesterol, making lifestyle changes and taking routine cholesterol-lowering statin medications may not be sufficient in helping them reach their target cholesterol levels.

In patients with atherosclerosis and/or diabetes without a prior heart attack or stroke, evolocumab cut the risk for first ...